Vin Tangpricha
Overview
Explore the profile of Vin Tangpricha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
281
Citations
7319
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lertdetkajorn K, Cobb C, Kapolka R, Hunt W, Tangpricha V
AACE Clin Case Rep
. 2025 Feb;
11(1):32-35.
PMID: 39896950
Background/objective: Men with cystic fibrosis (CF) have a high prevalence of low testosterone levels. A recent retrospective study demonstrated a quarter of a cohort of men with CF had serum...
2.
Rothman M, Hamnvik O, Davidge-Pitts C, Safer J, Ariel D, Tangpricha V, et al.
Transgend Health
. 2024 Dec;
9(6):463-465.
PMID: 39735380
Injectable estrogens are options for gender-affirming hormone therapy per guidelines, which suggest intramuscular dosages of 5-30 mg every 2 weeks or 2-10 mg weekly with estradiol cypionate or valerate interchangeably....
3.
Bushnell C, Kernan W, Sharrief A, Chaturvedi S, Cole J, Cornwell 3rd W, et al.
Stroke
. 2024 Oct;
55(12):e344-e424.
PMID: 39429201
Aim: The "2024 Guideline for the Primary Prevention of Stroke" replaces the 2014 "Guidelines for the Primary Prevention of Stroke." This updated guideline is intended to be a resource for...
4.
Gupta P, Cunha L, Diego D, Tangpricha V
Endocr Pract
. 2024 Sep;
30(12):1206-1211.
PMID: 39306093
Objective: Gender-affirming hormone therapy (GAHT) is often used by transgender and gender-diverse individuals to align their physical appearance with their gender identity. Discontinuation rates and factors leading to discontinuation of...
5.
Suppakitjanusant P, Wang Y, Sivapiromrat A, Hu C, Binongo J, Hunt W, et al.
J Clin Transl Endocrinol
. 2024 Aug;
37:100362.
PMID: 39188269
Background: Cystic fibrosis (CF) is a multi-organ disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR). Individuals with CF often have gastrointestinal (GI) dysbiosis due to chronic...
6.
Siira M, Getahun D, Silverberg M, Tangpricha V, Goodman M, Yeung H
Ann Epidemiol
. 2024 Jul;
97:11-15.
PMID: 39004237
Purpose: Transgender and gender-diverse (TGD) people may have been disproportionately impacted by the COVID-19 pandemic, yet little is known about vaccination status in this population. This multicenter cohort study of...
7.
Jathal I, Wang Y, Binongo J, Cobb C, Hunt W, Khan F, et al.
Am J Med Sci
. 2024 Jul;
368(6):637-647.
PMID: 38997066
Background: Men with cystic fibrosis (CF) have sexual health concerns such as delayed puberty, infertility, and hypogonadism. The causes and prevalence of hypogonadism have not been well studied. The purpose...
8.
9.
Anike O, Zhang Q, Bhasin S, Flanders W, Getahun D, Haw J, et al.
J Clin Endocrinol Metab
. 2024 May;
110(1):289-296.
PMID: 38815002
Context: The long-term effect of gender-affirming hormone therapy (GAHT) on glucose metabolism is an area of priority in transgender health research. Objectives: To evaluate the relation between GAHT and changes...
10.
Kazmerski T, Moy C, Aliaj E, Hudson J, Wright B, Poranski M, et al.
J Cyst Fibros
. 2024 Mar;
23(4):639-646.
PMID: 38485603
Background: To address sexual and reproductive health (SRH) concerns among people with cystic fibrosis(PwCF), the CF Foundation created the Sexual Health, Reproduction, and Gender Research (SHARING) Working Group. This report...